Full Text
EE344 Cost per Responder Associated with Bimekizumab Against Il-17A-Inhibitors in the Treatment of Axial Spondyloarthritis in Sweden

Abstract

Authors

M. Mørup K. Geale A. Ferguson A. Engström D. Willems

Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×